Skip to main content

Gilead Sciences, Inc 10-Q for FY2026 Q3

Gilead Sciences, Inc. (GILD)

10-Q 2026-10-30 For: 2026-09-30
View Original
Added on October 30, 2026

About this 10-Q

Gilead Sciences, Inc filed this 10-Q on October 30, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Gilead reported a nine-month net loss of $6.0 billion, driven by $11.3 billion in acquired IPR&D from acquisitions including Arcellx, Tubulis and Ouro Medicines. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$8.3B
up 6.8% from $7.77B a year earlier
Net income
$2.43B
down 20.4% from net income of $3.05B a year earlier
Diluted EPS
$1.94
down 20.2% from $2.43 a year earlier